Abortion, Induced

• 

  Subject Areas on Research

  • A new abortion technique: intravaginal and intramuscular prostaglandin. 
  • Abortion provision among practicing obstetrician-gynecologists. 
  • Afterword: Giving good advice: it is not what doctors say, but how they say it. 
  • An analysis of the reasons for Japan's low infant mortality rate. 
  • An effective strategy for decontamination, ex vivo expansion, and storage of human fetal liver hematopoietic stem cells. 
  • Back to the future: The AMA and religion, 1961-1974. 
  • Bacterial and fungal contamination of human fetal liver collected transvaginally for hematopoietic stem cell transplantation. 
  • Cardiovascular malformations: changes in prevalence and birth status, 1972-1990. 
  • Cervical priming prior to dilatation and evacuation: a comparison of methods. 
  • Cervical priming prior to first-trimester suction abortion with a single 15-methyl-prostaglandin F2 alpha vaginal suppository. 
  • Community-wide job loss and teenage fertility: evidence from North Carolina. 
  • Comparison of prostaglandin F2alpha and hypertonic saline for induction of midtrimester abortion. 
  • Continuous extraovular administration of prostaglandin F2alpha for midtrimester abortion. 
  • Continuous prostaglandin-F 2 infusion for middle-trimester abortion. 
  • Early pregnancy interruption with two 15-ME-PGF2a suppositories. 
  • Effects of smoking and of induced abortion on pregnancy outcome. 
  • Family planning, race consciousness and the fear of race genocide. 
  • Health services utilization after induced abortions in Ontario: a comparison between community clinics and hospitals. 
  • Hormone release and abortifacient effectiveness of a newly developed silastic device containing 15-ME-PGF2alpha methyl ester in concentrations of 0.5% and 1.0%. 
  • Induction of midtrimester abortion by serial intravaginal administration of 15(S)-15-methyl-prostaglandin F2alpha (THAM) suppositories. 
  • Killing versus totally disabling: a reply to critics. 
  • Knowledge of termination of pregnancy (TOP) legislation and attitudes toward TOP clinical training among medical students attending two South African universities. 
  • Management of failed prostaglandin abortions. 
  • Mid-trimester abortion induced by intravaginal administration of prostaglandin E2 suppositories. 
  • Midtrimester abortion induced by serial intramuscular injections of 15(S)-15-methyl-prostaglandin E2 methyl ester. 
  • Midtrimester abortion induced by serial intramuscular injections of 15(S)-15-methyl-prostaglandin F2alpha. 
  • Midtrimester abortion induced by serial intravaginal administration of prostaglandin E2 suppositories in conjunction with a contraceptive diaphragm. 
  • Midtrimester abortion induced by single intra-amniotic instillation of two dose schedules of 15(S)-15-methyl-prostaglandin F2alpha. 
  • Midtrimester abortion induced with a single intra-amniotic instillation of prostaglandin F2 alpha. 
  • Obstetrician-gynecologists' objections to and willingness to help patients obtain an abortion. 
  • Of more than one mind: obstetrician-gynecologists' approaches to morally controversial decisions in sexual and reproductive healthcare. 
  • Predictors of vaginal bleeding during the first two trimesters of pregnancy. 
  • Pregnancy-associated group B streptococcal endocarditis: a report of two fatal cases. 
  • Prenatal diagnosis of Duchenne muscular dystrophy by fetal muscle biopsy. 
  • Prenatal diagnosis of mosaic trisomy 13: a case report. 
  • Previous cesarean section, placenta increta, and uterine rupture in second-trimester abortion. 
  • Relationship of psychiatric illness to childbearing status: a hospital-based epidemiologic study. 
  • Religion in Organized Medicine: The AMA's Committee and Department of Medicine and Religion, 1961-1974. 
  • Reproductive and family planning history, knowledge, and needs: a community survey of low-income women in Beijing, China. 
  • Scientific and ethical concerns in neural fetal tissue transplantation. 
  • Serial intramuscular injections of 15(S)-15-methyl-prostaglandin F2alpha in the induction of abortion. 
  • Sex as contract: abortion and expanded choice. 
  • Termination of midtrimester pregnancy by serial intramuscular injections of 15(S)-15-methyl-prostaglandin F2alpha. 
  • The abortifacient and oxytocic effects of an intravaginal silicone rubber device containing a 0.5% concentration of 15(S)-15-methyl-prostaglandin F2alpha methyl ester. 
  • The abortifacient effectiveness and plasma prostaglandin concentrations with 15(S)-15-methyl prostaglandin F2alpha methyl ester-containing vaginal silastic devices. 
  • The abortifacient effects of a newly developed vaginal silastic device impregnated with an 0.5% concentration of 15(S)-15-methyl-prostaglandin F2alpha methyl ester in the first trimester. 
  • The effect of a 10 cm2, 0.5% 15-ME-PGF2alpha methyl ester intravaginal silastic device on abortion and plasma prostaglandin concentration. 
  • The effects of intramuscular injections of 15(S)-15-methyl prostaglandin F2alpha in failed abortions. 
  • The role of a long-acting vaginal suppository of 15-ME-PGF2 alpha in first and second trimester abortion. 
  • Ultrasound of the postpartum uterus. Prediction of retained placental tissue. 
  • Would you terminate a pregnancy affected by sickle cell disease? Analysis of views of patients in Cameroon. 
• 

  Keywords of People

  • Ostbye, Truls, Professor in Community and Family Medicine, Community and Family Medicine
  • Sinnott-Armstrong, Walter, Chauncey Stillman Professor of Practical Ethics, Duke Science & Society